NASDAQ:PPCB Propanc Biopharma (PPCB) Stock Price, News & Analysis $0.34 +0.00 (+0.15%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$0.32 -0.02 (-6.43%) As of 10/16/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Propanc Biopharma Stock (NASDAQ:PPCB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Propanc Biopharma alerts:Sign Up Key Stats Today's Range$0.33▼$0.4050-Day Range$0.34▼$2.2352-Week Range$0.33▼$41.25Volume2.02 million shsAverage Volume272,492 shsMarket Capitalization$2.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Propanc Biopharma, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors. The company’s research centers on proenzyme-based cancer therapies designed to target the tumor microenvironment and address cancer recurrence and metastasis. Propanc’s lead investigational product is PRP, a formulation of two digestive proenzymes, trypsinogen and chymotrypsinogen. The company is developing PRP for potential use against advanced and recurrent cancers, including pancreatic, ovarian and colorectal cancers. The therapy is intended to become selectively activated in the tumor environment, where it may help inhibit tumor growth and the spread of cancer cells. Propanc Biopharma was established in Australia and has pursued development activities through its operations there and in the United States. The company’s leadership includes Chief Executive Officer and Executive Chairman James Nathanielsz. As a development-stage biotechnology company, Propanc’s products remain investigational and require further clinical and regulatory evaluation before they can be commercially marketed.AI Generated. May Contain Errors. Read More Propanc Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScorePPCB MarketRank™: 0.47355393434 of 5 starsPropanc Biopharma scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingPropanc Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePropanc Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Propanc Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPropanc Biopharma has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.38% of the float of Propanc Biopharma has been sold short.Short Interest Ratio / Days to CoverPropanc Biopharma has a short interest ratio ("days to cover") of 0.21, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Propanc Biopharma has recently increased by 145.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPropanc Biopharma does not currently pay a dividend.Dividend GrowthPropanc Biopharma does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.10 News SentimentPropanc Biopharma has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Propanc Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for PPCB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Propanc Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders28.67% of the stock of Propanc Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsPropanc Biopharma has minimal institutional ownership at this time.Read more about Propanc Biopharma's insider trading history. Receive PPCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPCB Stock News HeadlinesPropanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer CellsOctober 16 at 12:25 PM | markets.businessinsider.comPropanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer CellsOctober 16 at 8:36 AM | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian CancerOctober 14 at 8:30 AM | globenewswire.comPropanc Biopharma Inc (NASDAQ:PPCB) Sees Large Increase in Short InterestOctober 13, 2026 | americanbankingnews.comPropanc Reports Positive Preclinical Pancreatic Cancer Data For PRP; Phase 1b Planned In Q1 2027October 8, 2026 | rttnews.comPropanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ DaraxonrasibOctober 7, 2026 | markets.businessinsider.comPropanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' DaraxonrasibOctober 7, 2026 | globenewswire.comSee More Headlines PPCB Stock Analysis - Frequently Asked Questions How have PPCB shares performed this year? Propanc Biopharma's stock was trading at $13.4150 at the start of the year. Since then, PPCB stock has decreased by 97.5% and is now trading at $0.3420. How were Propanc Biopharma's earnings last quarter? Propanc Biopharma Inc (NASDAQ:PPCB) announced its earnings results on Friday, September, 25th. The company reported ($1.77) earnings per share for the quarter. When did Propanc Biopharma's stock split? Shares of Propanc Biopharma reverse split on Tuesday, May 23rd 2023.The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How will Propanc Biopharma's stock buyback program work? Propanc Biopharma's board initiated a share repurchase program on Thursday, July 2nd 2026, which allows the company to buy back $500,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 15,243,902.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company's management believes its stock is undervalued. When did Propanc Biopharma IPO? Propanc Biopharma (PPCB) raised $5 million in an initial public offering on Friday, August 15th 2025. The company issued 1,000,000 shares at a price of $4.00-$6.00 per share. D. Boral Capital (ex-EF Hutton) and Craft Capital served as the underwriters for the IPO. How do I buy shares of Propanc Biopharma? Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Propanc Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Propanc Biopharma investors own include Corbus Pharmaceuticals (CRBP), Delcath Systems (DCTH), C3.ai (AI), Petroteq Energy (PQEFF), AMC Entertainment (AMC), Aurora Cannabis (ACBFF) and AbbVie (ABBV). Company Calendar Last Earnings9/25/2026Today10/16/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PPCB Previous SymbolOTCMKTS:PPCB CIK1517681 Webwww.propanc.com Phone(139) 882-0780Fax61 03 9882 9969Employees2Year Founded2007Profitability EPS (Trailing Twelve Months)($24.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-171.31% Return on Assets-125.33% Debt Debt-to-Equity RatioN/A Current Ratio2.55 Quick Ratio2.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.84 per share Price / Book0.12Miscellaneous Outstanding Shares6,330,000Free Float4,516,000Market Cap$2.16 million OptionableNot Optionable Beta3.53 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:PPCB) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Propanc Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
